| RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines L Shen, J Zhang, HJ Lee, MT Batista, SA Johnston Scientific reports 9 (1), 14184, 2019 | 49 | 2019 |
| Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications R Moretto, A Elliott, J Zhang, H Arai, MM Germani, V Conca, J Xiu, ... JNCI: Journal of the National Cancer Institute 114 (2), 271-279, 2022 | 37 | 2022 |
| The landscape of alterations in DNA damage response pathways in colorectal cancer H Arai, A Elliott, J Xiu, J Wang, F Battaglin, N Kawanishi, S Soni, W Zhang, ... Clinical cancer research 27 (11), 3234-3242, 2021 | 34 | 2021 |
| Using frameshift peptide arrays for cancer neo-antigens screening J Zhang, L Shen, SA Johnston Scientific reports 8 (1), 17366, 2018 | 17 | 2018 |
| Acquired tertiary MET resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a patient with KIF5B-RET–positive NSCLC with Secondary MET … VW Zhu, SS Zhang, J Zhang, J Swensen, J Xiu, SHI Ou Journal of Thoracic Oncology 16 (7), e51-e54, 2021 | 14 | 2021 |
| Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model M Peterson, SN Murphy, J Lainson, J Zhang, L Shen, CW Diehnelt, ... BMC immunology 21, 1-15, 2020 | 11 | 2020 |
| Characterization of MET exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing SY Kim, J Yin, S Bohlman, P Walker, S Dacic, C Kim, H Khan, SV Liu, ... JTO Clinical and Research Reports 3 (9), 100381, 2022 | 10 | 2022 |
| Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer H Arai, A Elliott, J Millstein, J Xiu, FS Ou, F Innocenti, J Wang, F Battaglin, ... Oncogene 41 (2), 260-267, 2022 | 7 | 2022 |
| The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC) H Arai, A Elliott, J Wang, F Battaglin, S Soni, W Zhang, D Sohal, ... J Clin Oncol 38 (15_suppl), 4064, 2020 | 4 | 2020 |
| Predicted immunogenicity of CDK12 Biallelic loss-of-function tumors Varies across cancer types A Elliott, J Zhang, Q Zhang, J Swensen, D Martin, J Xiu, DM Geynisman, ... The Journal of Molecular Diagnostics 23 (12), 1761-1773, 2021 | 3 | 2021 |
| Globo H expression in metastatic colorectal cancer (CRC) P Jayachandran, Y Baca, J Xiu, J Zhang, F Battaglin, H Arai, RM Goldberg, ... J. Clin. Oncol 39, 3527-3527, 2021 | 1 | 2021 |
| FAST vaccines based on frameshift neoantigens may have advantages over personal vaccines MT Batista, SN Murphy, J Zhang, L Shen, P Stafford, SA Johnston Cancer Research 79 (13), 2019 | 1 | 2019 |
| Frameshift Antigens for Cancer Vaccine Development J Zhang Arizona State University, 2018 | 1 | 2018 |
| Overexpression of KMT2A is associated with worse prognosis and specific immune signatures in patients with TP53-mutated hepatocellular carcinomas L Sha COMPLEMENT 1 (1.1), 1.2, 2022 | | 2022 |
| Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers. F Battaglin, A Elliott, J Zhang, P Stafford, A Helmstetter, MJ Oberley, ... Journal of Clinical Oncology 40 (4_suppl), 246-246, 2022 | | 2022 |
| Fusion-associated neoantigen burden and predicted immunogenicity of CDK12 biallelic loss-of-function tumors vary substantially across cancer types A Elliott, P Stafford, J Zhang, Q Zhang, J Swensen, D Martin, J Xiu, ... Cancer research (Chicago, Ill.) 80 (16_Supplement), 3639-3639, 2020 | | 2020 |
